| Note | |
| | |
| Entity | Lung cancer |
| Note | SOCS-3 acts as a tumor suppressor and is frequently lost in the disease. Its transient transfection in lung cancer cell lines leads to a decrease in proliferation. |
| | |
| | |
| Entity | Liver cancer |
| Note | SOCS-3 is silenced by methylation. SOCS-3 is a tumor suppressor in this malignancy. It is implicated in regulation of migration of cancer cells. SOCS-3 deletion enhances JAK/STAT and FAK signaling. |
| | |
| | |
| Entity | Barret's adenocarcinoma |
| Note | SOCS-3 is methylated. It is considered as a tumor suppressor. |
| | |
| | |
| Entity | Glioblastoma multiforme |
| Note | SOCS-3 expression is lost through promoter methylation. |
| | |
| | |
| Entity | Head and neck squamous cell cancer |
| Note | SOCS-3 is frequently down-regulated as a result of promoter methylation. It causes a growth inhibition. |
| | |
| | |
| Entity | Hematological malignancies |
| Note | SOCS-3 inhibits megakaryocytic growth, overexpression of SOCS-3 is associated with a decreased survival of patients with follicular lymphoma. |
| | |
| | |
| Entity | Melanoma |
| Note | SOCS-3 is a tumor promoter in melanoma and is constitutively expressed in several cell lines. |
| | |
| | |
| Entity | Prostate cancer |
| Note | SOCS-3 stimulates proliferation and inhibits apoptosis in prostate cancer cells which do not express the androgen receptor. It may also antagonize the effects of fibroblasts growth factor and mitogen-activated protein kinases. In androgen-sensitive prostate cancer cells, SOCS-3 is induced by androgen and may inhibit androgen-stimulated proliferation and secretion. |
| | |
| | |
| Entity | Diabetes |
| Note | SOCS-3 may antagonize function of insulin-like growth factors. |
| | |
| | |
| Entity | Various cancers |
| Prognosis | Loss of protein expression and promoter hypermethylation occur in lung, liver cancer, head and neck squamous cell cancer. Overexpression occurs in melanoma and prostate cancer. |
| | |
| Suppressor of cytokine signaling-3 antagonizes cAMP effects on proliferation and apoptosis and is expressed in human prostate cancer. |
| Bellezza I, Neuwirt H, Nemes C, Cavarretta IT, Puhr M, Steiner H, Minelli A, Bartsch G, Offner F, Hobisch A, Doppler W, Culig Z. |
| Am J Pathol. 2006 Dec;169(6):2199-208. |
| PMID 17148681 |
| |
| STAT3-mediated constitutive expression of SOCS-3 in cutaneous T-cell lymphoma. |
| Brender C, Nielsen M, Kaltoft K, Mikkelsen G, Zhang Q, Wasik M, Billestrup N, Odum N. |
| Blood. 2001 Feb 15;97(4):1056-62. |
| PMID 11159537 |
| |
| Epigenetic inactivation of suppressors of cytokine signalling in Philadelphia-negative chronic myeloproliferative disorders. |
| Capello D, Deambrogi C, Rossi D, Lischetti T, Piranda D, Cerri M, Spina V, Rasi S, Gaidano G, Lunghi M. |
| Br J Haematol. 2008 May;141(4):504-11. Epub 2008 Mar 3. |
| PMID 18318760 |
| |
| SOCS-3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancer. |
| He B, You L, Uematsu K, Zang K, Xu Z, Lee AY, Costello JF, McCormick F, Jablons DM. |
| Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):14133-8. Epub 2003 Nov 14. |
| PMID 14617776 |
| |
| Constitutive suppressor of cytokine signaling 3 expression confers a growth advantage to a human melanoma cell line. |
| Komyod W, Bohm M, Metze D, Heinrich PC, Behrmann I. |
| Mol Cancer Res. 2007 Mar;5(3):271-81. |
| PMID 17374732 |
| |
| Prognostic relevance of SOCS3 hypermethylation in patients with glioblastoma multiforme. |
| Martini M, Pallini R, Luongo G, Cenci T, Lucantoni C, Larocca LM. |
| Int J Cancer. 2008 Dec 15;123(12):2955-60. |
| PMID 18770864 |
| |
| Methylation silencing of SOCS-3 promotes cell growth and migration by enhancing JAK/STAT and FAK signalings in human hepatocellular carcinoma. |
| Niwa Y, Kanda H, Shikauchi Y, Saiura A, Matsubara K, Kitagawa T, Yamamoto J, Kubo T, Yoshikawa H. |
| Oncogene. 2005 Sep 22;24(42):6406-17. |
| PMID 16007195 |
| |
| Type 2 diabetes impairs insulin receptor substrate-2-mediated phosphatidylinositol 3-kinase activity in primary macrophages to induce a state of cytokine resistance to IL-4 in association with overexpression of suppressor of cytokine signaling-3. |
| O'Connor JC, Sherry CL, Guest CB, Freund GG. |
| J Immunol. 2007 Jun 1;178(11):6886-93. |
| PMID 17513737 |
| |
| Down-regulation of suppressor of cytokine signaling-3 causes prostate cancer cell death through activation of the extrinsic and intrinsic apoptosis pathways. |
| Puhr M, Santer FR, Neuwirt H, Susani M, Nemeth JA, Hobisch A, Kenner L, Culig Z. |
| Cancer Res. 2009 Sep 15;69(18):7375-84. Epub 2009 Sep 8. |
| PMID 19738059 |
| |
| SOCS-3 is frequently methylated in head and neck squamous cell carcinoma and its precursor lesions and causes growth inhibition. |
| Weber A, Hengge UR, Bardenheuer W, Tischoff I, Sommerer F, Markwarth A, Dietz A, Wittekind C, Tannapfel A. |
| Oncogene. 2005 Oct 6;24(44):6699-708. |
| PMID 16007169 |
| |
